糖尿病前期心脏自主神经病变患病率的系统综述
该系统综述通过检索多个数据库评估糖尿病前期患者中心脏自主神经病变(CAN)的患病率。纳入11项研究共4431名参与者,其中糖尿病前期1730人。仅有6项研究报告了明确的CAN患病率(9-39%),一项基于人群的大型研究显示糖尿病前期CAN患病率为9%,高于正常糖耐量者的4.5%。
要点
- 糖尿病前期患者CAN患病率高于预期,约为9-39%。
- 基于人群的KORA S4研究显示糖尿病前期CAN患病率为9%,正常糖耐量为4.5%。
- 研究间异质性大,CAN定义和方法学差异影响患病率估计。
核心结论
- 糖尿病前期患者中CAN患病率高于预期,需考虑人群筛查以早期发现。
研究设计与样本
- 系统综述,检索MEDLINE、EMBASE、PubMed、Web of Science、Scopus和Cochrane数据库,纳入11项研究,总参与者4431人(糖尿病前期1730人,正常糖耐量1999人,主要为2型糖尿病702人)。
主要发现
- 6项研究报告明确CAN患病率为9-39%。
- KORA S4研究(1332名参与者)显示糖尿病前期总体CAN患病率为9%(孤立性IGT 5.9%,孤立性IFG 8.1%,IFG+IGT 11.4%),正常糖耐量为4.5%。
- 8项研究内糖尿病前期CAN患病率(9-38%)高于正常糖耐量(0-18%)。
- 5项研究报告基于一项自主神经功能试验阳性的可能CAN患病率,范围较宽。
关键数值与推荐
- 明确CAN基于两项或以上自主神经功能试验阳性。
- KORA S4研究中糖尿病前期CAN患病率为9%,正常糖耐量为4.5%。
临床怎么用
- 对糖尿病前期人群应考虑CAN筛查以早期发现,但需权衡筛查的获益与风险。
局限性
- 研究间存在异质性,CAN定义、方法和人群特征不同,导致患病率估计差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Cardiac autonomic neuropathy (CAN) is independently associated with silent myocardial ischaemia, major cardiovascular events, myocardial dysfunction and cardiovascular mortality. Several studies have highlighted the increased prevalence of CAN in prediabetes (impaired glucose tolerance and/or impaired fasting glucose). Considering the exponential rise of prediabetes, we aimed to determine the prevalence of CAN through a systematic literature review. METHODS: This systematic review was registered with PROSPERO (CRD42019125447). An electronic literature search was performed using MEDLINE, EMBASE, PubMed, Web of Science, Scopus and Cochrane databases. Published full text, English language articles that provide CAN prevalence data of studies in individuals with prediabetes and aged over 18 years were included. Prevalence data for normal glucose tolerance and diabetes were also extracted from the selected articles, if present. All articles were screened by two independent reviewers using a priori criteria. Methodological quality and risk of bias were evaluated using a critical appraisal tool. RESULTS: Database searches found 4500 articles; subsequently, 199 full text articles were screened, 11 of which fulfilled the inclusion criteria (4431 total participants, 1730 people with prediabetes, 1999 people with normal glucose tolerance [NGT] and 702 people with predominantly type 2 diabetes). Six of the selected studies reported definite CAN prevalence data (9-39%). Only a single large population-based study by Ziegler et al (KORA S4 study, 1332 participants) determined definite CAN based on two or more positive autonomic function tests (AFTs), with a mean prevalence of 9% in all prediabetes groups (isolated impaired glucose tolerance 5.9%; isolated impaired fasting glucose 8.1%; impaired fasting glucose plus impaired glucose tolerance 11.4%), which was higher than NGT (4.5%). This study is most likely to provide a reliable population-specific estimate of CAN in prediabetes. There was a higher than expected prevalence of CAN in prediabetes (9-38%) when compared with normal glucose tolerance (0-18%) within the same studies (n = 8). There was a wide prevalence of possible CAN based on one positive AFT (n = 5). There was heterogeneity between the studies with variations in the definition of CAN, methodology and characteristics of the populations, which likely contributed to the diversity of prevalence estimates. The overall risk of bias was low. CONCLUSIONS/INTERPRETATION: There is a higher than expected prevalence of CAN in prediabetes. Early detection of CAN in prediabetes through population screening needs careful consideration in view of the excess morbidity and mortality risk associated with this condition. Graphical abstract.
引用
- Eleftheriadou A, Williams S, Nevitt S, et al. The prevalence of cardiac autonomic neuropathy in prediabetes: a systematic review. Diabetologia. 2020. PMID: 33164108. doi:10.1007/s00125-020-05316-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。